How TOPAMAX Can Help
Freedom From Seizures Is the Goal
TOPAMAX may help you reach your ultimate goal—freedom from seizures.
TOPAMAX has a proven safety and efficacy profile and is a generally well-tolerated antiseizure medicine, proven to be effective in controlling a broad range of seizures in adults and children age 2 or older.
TOPAMAX Works Well With Other Antiepileptic Drugs
Because TOPAMAX works well with other medicines, it may also be prescribed along with another antiepileptic drug for patients who are still having seizures while taking the other treatment.
In combination with other antiepileptic drugs, TOPAMAX has been proven to be effective at controlling seizures in adults and children age 2 or older who have:
- Partial-onset seizures
- Primary generalized tonic-clonic seizures
- Seizures associated with Lennox-Gastaut syndrome
TOPAMAX: Used by Millions Since 1997
Since its introduction in the U.S. in 1997, TOPAMAX has helped many people to achieve better control of their seizures. Other facts you should know about TOPAMAX are listed below.
- TOPAMAX has a proven safety profile.
- More than 4 million people worldwide have taken topiramate since it was first introduced, regardless of condition.
- TOPAMAX is not associated with drug-induced weight gain.
- TOPAMAX can be combined with many other medicines that you may be taking.
TOPAMAX May Be Right for You
Just as every person is different, so is every antiseizure medication. Because different people do not always respond in exactly the same way to the same medicine, you may need to try several medicines before you find the medicine (or combination of medicines) that does the best job of controlling your seizures with the fewest side effects. Your healthcare professional can work with you to find the treatment that is best for you.
TOPAMAX Offers Treatment Support
Treatment support can make a difference. If you or your loved one are taking TOPAMAX, join
the FREE Everyday Essentials™ support program and learn how to get the most out of your treatment. Benefits
include expert answers to your treatment questions, product rebates, support giver information, help
finding resources in your area—and much more.
The Everyday Essentials™ Program
Get expert answers, help finding resources in your area, and more. Join Now
About TOPAMAX
TOPAMAX is approved as initial monotherapy in patients 10 years of age and older with partial-onset
or primary generalized tonic-clonic seizures.
Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more
than 2 seizures in the 3 months prior to enrollment. Safety and effectiveness in patients
who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not
been established in controlled trials.
TOPAMAX is approved as add-on therapy for patients 2 years of age and older with primary generalized
tonic-clonic seizures, partial-onset seizures, or seizures associated with Lennox-Gastaut syndrome.
Important Safety Information
Serious risks associated with TOPAMAX include lowered bicarbonate levels in the blood resulting in an
increase in the acidity of the blood (metabolic acidosis). Symptoms could include hyperventilation
(rapid, deep breathing), tiredness, loss of appetite, irregular heartbeat or changes in the level of alertness.
Call your doctor immediately if you get these symptoms. Your doctor may want to do simple blood tests. Chronic,
untreated metabolic acidosis may increase the risk for kidney stones or bone disease.
Other serious risks include decreased sweating, increased body temperature, kidney stones, sleepiness,
dizziness, confusion, difficulty concentrating, and increased eye pressure (glaucoma). Call your doctor
immediately if you have any decrease in vision or eye pain. These problems can lead to blindness if not
treated right away.
More common side effects in adults are nervousness, coordination problems, fatigue, speech problems, slowed
thinking, memory difficulty, tingling in arms and legs, and double vision; and in children, fatigue, loss of appetite,
nervousness, memory difficulty, aggressive behavior, and weight loss.
As monotherapy, the most common side effects of TOPAMAX (in the 400 mg/day group and at a rate higher than the 50
mg/day group) in adults were tingling in arms and legs, weight decrease, sleepiness, loss of appetite, dizziness, and
difficulty with memory; and in children, weight decrease, upper respiratory tract infection, tingling in arms and legs,
loss of appetite, diarrhea, and mood problems.
In combination with other antiepileptic drugs (AEDs), the most common side effects of TOPAMAX in adults (200 to 400 mg/day)
were sleepiness, dizziness, nervousness, loss of muscle coordination, fatigue, speech disorders and related problems, psychomotor
slowing, abnormal vision, difficulty with memory, tingling in arms and legs, and double vision; and in children (5 to 9 mg/kg/day), fatigue,
sleepiness, loss of appetite, nervousness, difficulty with concentration/attention, difficulty with memory, aggressive reaction, and weight decrease.
Tell your doctor about other medications you take.
Please see full U.S. Prescribing Information.
© Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1999-2008. All rights reserved.
Your use of the information on this site is subject to the terms of our Legal Statement. Please see our Privacy Policy.
This site is published by Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., which is solely responsible for its contents.
Capitalized product names are trademarks of Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
This information is intended for use by our customers, patients and healthcare professionals in the United States only. Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside the United States.
This site was last modified on: Jul 26 2007 at 13:45:29 EDT